- Home
- DTSS vs APM Comparison
DTSS vs APM Comparison
Compare DTSS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- APM
- Stock Information
- Founded
- DTSS 2014
- APM 2010
- Country
- DTSS China
- APM United Kingdom
- Employees
- DTSS N/A
- APM N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- APM Health Care
- Exchange
- DTSS Nasdaq
- APM Nasdaq
- Market Cap
- DTSS 16.5M
- APM 18.9M
- IPO Year
- DTSS N/A
- APM 2018
- Fundamental
- Price
- DTSS $2.09
- APM $1.98
- Analyst Decision
- DTSS
- APM
- Analyst Count
- DTSS 0
- APM 0
- Target Price
- DTSS N/A
- APM N/A
- AVG Volume (30 Days)
- DTSS 91.7K
- APM 20.5M
- Earning Date
- DTSS 11-12-2025
- APM 04-30-2025
- Dividend Yield
- DTSS N/A
- APM N/A
- EPS Growth
- DTSS N/A
- APM N/A
- EPS
- DTSS N/A
- APM N/A
- Revenue
- DTSS $56,255,129.00
- APM N/A
- Revenue This Year
- DTSS N/A
- APM N/A
- Revenue Next Year
- DTSS N/A
- APM N/A
- P/E Ratio
- DTSS N/A
- APM N/A
- Revenue Growth
- DTSS 144.20
- APM N/A
- 52 Week Low
- DTSS $1.63
- APM $0.46
- 52 Week High
- DTSS $3.55
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- DTSS 52.36
- APM 52.67
- Support Level
- DTSS $1.95
- APM $1.64
- Resistance Level
- DTSS $2.30
- APM $2.65
- Average True Range (ATR)
- DTSS 0.14
- APM 0.21
- MACD
- DTSS 0.01
- APM -0.05
- Stochastic Oscillator
- DTSS 47.50
- APM 33.66
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.